Precision BioSciences reports HBV clinical milestone
PBGENE-HBV achieved first biopsy evidence of cccDNA elimination, while the company reported Q2 2026 results and a cash balance of $112.4 million.
View filing at SEC.gov →4 most recent filings and news items mentioning DTIL. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/DTIL/news?limit=20"
Pull DTIL filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayPBGENE-HBV achieved first biopsy evidence of cccDNA elimination, while the company reported Q2 2026 results and a cash balance of $112.4 million.
View filing at SEC.gov →Precision BioSciences announced the promotion of Alex Kelly to COO and Naresh Tanna to CFO. These changes support the advancement of its gene editing programs PBGENE-HBV and PBGENE-DMD.
View filing at SEC.gov →Precision BioSciences announced late-breaking clinical data from the ELIMINATE-B study demonstrating that PBGENE-HBV directly eliminated cccDNA with a 10-fold reduction in viral transcripts and achieved pgRNA loss in 100% of treated patients. The data represent a potential breakt
View filing at SEC.gov →Precision BioSciences adopted a certificate amendment expanding protections for directors and officers from personal liability for breaches of fiduciary duty, subject to Delaware law limits. The amendment enhances corporate governance flexibility and director indemnification prov
View filing at SEC.gov →